✨ Medicine Consents
NEW ZEALAND GAZETTE
16 MAY
1301
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Ursodeoxycholic acid 150 mg, 300 mg | Capsules | Ciba-Geigy AG., Stein, Switzerland and Giuliani SpA., Cernusco Sul Naviglio, Milan, Italy | Actigall |
Note: Provisional consent for this product expires on 7 September 1997.
Dated this 14th day of May 1996.
HUGH BABER, Assistant General Manager, Health Regulation and Protection, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.
go3160
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name |
|---|---|---|---|
| Ipratropium bromide monohydrate 21 mcg equivalent to 20 mcg ipratropium bromide anhydrous per actuation | Spray, oral metered dose | Boehringer Ingelheim KG., Ingelheim am Rhein, Germany | Atrovent Autohaler |
| Ganciclovir sodium 250 mg | Capsule | Syntex Puerto Rico Inc., Humacao, Puerto Rico | Cymevene |
| Lactulose 100% in 10 g, 150 g, 200 g, 350 g, 700 g | Powder for oral solution | Solvay-Duphar BV., The Netherlands | Duphalac Dry |
| Lignocaine 2.5%: prilocaine hydrochloride 2.5% | Cream | Astra Pharmaceutical Production AB, Södertälje, Sweden | Emla Sterile Cream 5% |
| Estradiol 0.75 mg (delivery rate 25 mcg per day), 1.5 mg (delivery rate 50 mcg per day), 3 mg (delivery rate 100 mcg per day) | Transdermal patch | Lohmann Therapie Systeme GmbH & Co KG, Andernach, Germany | Estraderm MX |
| Fluticasone propionate 50 mcg, 100 mcg, 250 mcg, 500 mcg | Powder for oral inhalation | Glaxo Operations UK Limited, Ware, Hertfordshire, United Kingdom | Flixotide Accuhaler |
| Lenograstim 105 mcg | Injection, powder for | Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan | Granocyte 13 |
| Lenograstim 263 mcg | Injection, powder for | Chugai Pharmaceutical Co Limited, Utsunomiya, Tochigi, Japan | Granocyte 34 |
| Human immunoglobulin G 60 mg/mL in 50 mL, 200 mL, 500 mL | Injection, solution | CSL Limited, Broadmeadows, Victoria, Australia | Intragam |
| Tibolone 2.5 mg | Tablet | Organon International BV., Oss, The Netherlands | Livial |
| Gadopentetate dimeglumine 469 mg per mL in 5 mL, 10 mL, 15 mL and 20 mL | Injection | Schering AG., Berlin, Germany | Magnevist |
| Tretinoin 0.05% w/w | Cream | Cilag AG., Schaffhausen, Switzerland; Johnson & Johnson Medical Products Pty Limited, North Ryde, Sydney, New South Wales, Australia; Ortho Pharmaceuticals Inc., Bo Campo Alegre Manati, Puerto Rico and Ortho Pharmaceuticals Corporation, Raritan, New Jersey, United States of America | Retinova Emollient |
Dated this 14th day of May 1996.
HUGH BABER, Assistant General Manager, Health Regulation and Protection, pursuant to delegation given by the Minister of Health on the 18th day of January 1996.
go3161
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1996, No 48
NZLII —
NZ Gazette 1996, No 48
✨ LLM interpretation of page content
🏥
Consent to the Distribution of a New Medicine
(continued from previous page)
🏥 Health & Social Welfare14 May 1996
Medicines Act, New Medicine, Ursodeoxycholic acid, Actigall
- Hugh Baber, Assistant General Manager, Health Regulation and Protection
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare14 May 1996
Medicines Act, Changed Medicines, Ipratropium bromide, Ganciclovir sodium, Lactulose, Lignocaine, Estradiol, Fluticasone propionate, Lenograstim, Human immunoglobulin G, Tibolone, Gadopentetate dimeglumine, Tretinoin
- Hugh Baber, Assistant General Manager, Health Regulation and Protection